BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 12519390)

  • 1. In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids.
    Goddard RV; Prentice AG; Copplestone JA; Kaminski ER
    Clin Exp Immunol; 2003 Jan; 131(1):82-9. PubMed ID: 12519390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate.
    Goddard RV; Prentice AG; Copplestone JA; Kaminski ER
    Clin Exp Immunol; 2001 Oct; 126(1):16-28. PubMed ID: 11678895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of in vitro B-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotic tumor lysate.
    Suresh K; Fraser G; Scheid E; Leber B; Gauldie J; Foley R
    Leuk Lymphoma; 2006 Feb; 47(2):297-306. PubMed ID: 16321861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL.
    Kokhaei P; Choudhury A; Mahdian R; Lundin J; Moshfegh A; Osterborg A; Mellstedt H
    Leukemia; 2004 Nov; 18(11):1810-5. PubMed ID: 15385926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of the proteins responsible for stimulating B-CLL-specific T-cell responses by autologous dendritic cells pulsed with tumour cell lysate.
    Goddard R; Prentice A; Copplestone A; Kaminski E
    Hematol J; 2003; 4(4):271-6. PubMed ID: 12872152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs.
    Aloysius MM; Mc Kechnie AJ; Robins RA; Verma C; Eremin JM; Farzaneh F; Habib NA; Bhalla J; Hardwick NR; Satthaporn S; Sreenivasan T; El-Sheemy M; Eremin O
    J Transl Med; 2009 Mar; 7():18. PubMed ID: 19298672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
    Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
    Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells.
    Müller MR; Tsakou G; Grünebach F; Schmidt SM; Brossart P
    Blood; 2004 Mar; 103(5):1763-9. PubMed ID: 14615377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour-loaded α-type 1-polarized dendritic cells from patients with chronic lymphocytic leukaemia produce a superior NK-, NKT- and CD8+ T cell-attracting chemokine profile.
    Gustafsson K; Junevik K; Werlenius O; Holmgren S; Karlsson-Parra A; Andersson PO
    Scand J Immunol; 2011 Sep; 74(3):318-326. PubMed ID: 21595737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application.
    Trevor KT; Cover C; Ruiz YW; Akporiaye ET; Hersh EM; Landais D; Taylor RR; King AD; Walters RE
    Cancer Immunol Immunother; 2004 Aug; 53(8):705-14. PubMed ID: 15048588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response.
    Santodonato L; D'Agostino G; Nisini R; Mariotti S; Monque DM; Spada M; Lattanzi L; Perrone MP; Andreotti M; Belardelli F; Ferrantini M
    J Immunol; 2003 May; 170(10):5195-202. PubMed ID: 12734367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia.
    Lee JJ; Foon KA; Mailliard RB; Muthuswamy R; Kalinski P
    J Leukoc Biol; 2008 Jul; 84(1):319-25. PubMed ID: 18426971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional monocyte-derived dendritic cells can be generated in chronic lymphocytic leukaemia.
    Vuillier F; Maloum K; Thomas EK; Jouanne C; Dighiero G; Scott-Algara D
    Br J Haematol; 2001 Dec; 115(4):831-44. PubMed ID: 11843817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human dendritic cells pulsed with autologous Epstein-Barr virus transformed B-cell lymphoblastoid cell (BCL) lysate elicit a BCL specific MHC-class II restricted T-cell response.
    Sugano M; Conway TF; Kelleher RJ; Sugiyama Y; Chen FA; Bankert RB; Bernstein SH
    J Exp Clin Cancer Res; 2001 Jun; 20(2):175-82. PubMed ID: 11484971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL.
    Kokhaei P; Rezvany MR; Virving L; Choudhury A; Rabbani H; Osterborg A; Mellstedt H
    Leukemia; 2003 May; 17(5):894-9. PubMed ID: 12750703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Generation of T cell-mediated antitumor response in vitro by autologous dendritic cells pulsed with tumor lysates in patients with non-small cell lung cancer].
    You J; Yu JP; Ren XB; Wang CL; Zhang P; Zhang XZ
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):333-6. PubMed ID: 15312341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of interleukin 21 on anti-leukemia activity of cytotoxic T lymphocytes induced by dendritic cells].
    Zhao MF; Zhai WJ; Deng Q; Li YM; Geng L; Yang L; Lv HR; Lin XM; Liu PJ; Li JL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):627-32. PubMed ID: 19549377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response.
    Hus I; Schmitt M; Tabarkiewicz J; Radej S; Wojas K; Bojarska-Junak A; Schmitt A; Giannopoulos K; Dmoszyńska A; Roliński J
    Leukemia; 2008 May; 22(5):1007-17. PubMed ID: 18323802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers.
    Bohnenkamp HR; Coleman J; Burchell JM; Taylor-Papadimitriou J; Noll T
    Cell Immunol; 2004; 231(1-2):112-25. PubMed ID: 15919376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.